All In Biotech

Drug Trial Radar · NCT06121843

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component

Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

187

Planned (sponsor's estimate)

Start

Feb 22, 2024

Primary completion

Aug 1, 2028

Study completion Aug 1, 2028

Sponsor

Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Nov 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

Conditions

  • Multiple Myeloma

Interventions

  • BMS-986393Drug

    Specified dose on specified days

  • AlnuctamabDrug

    Specified dose on specified days

  • MezigdomideDrug

    Specified dose on specified days

  • IberdomideDrug

    Specified dose on specified days

  • ElranatamabDrug

    Specified dose on specified days

  • DexamethasoneDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: Up to 2 years
  2. Incidence of serious adverse events (SAEs)Time frame: Up to 2 years
  3. Incidence of adverse events of special interest (AESI)Time frame: Up to 2 years
  4. Incidence of AEs leading to discontinuationTime frame: Up to 2 years
  5. Number of DeathsTime frame: Up to 2 years
  6. Establish recommended Phase 2 dose (RP2D)Time frame: Up to 2 years

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Mayo Clinic in Arizona - Phoenix

    Phoenix, Arizona · Recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Recruiting

  • Northside Hospital

    Atlanta, Georgia · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Clinic in Rochester, Minnesota

    Rochester, Minnesota · Recruiting

  • University Of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Roswell Park Cancer Institute

    Buffalo, New York · Recruiting

  • Laura and Isaac Perlmutter Cancer Center

    New York, New York · Recruiting

  • Local Institution - 0009

    New York, New York · Completed

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Local Institution - 0023

    Pittsburgh, Pennsylvania · Withdrawn

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Arthur J.E. Child Comprehensive Cancer Centre

    Calgary, Alberta, Canada · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.